A5026573275- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- Pituitary Gland Disorders and Treatments
- Gestational Trophoblastic Disease Studies
- Adrenal and Paraganglionic Tumors
- Radiopharmaceutical Chemistry and Applications
- Metastasis and carcinoma case studies
- Intraperitoneal and Appendiceal Malignancies
- Helicobacter pylori-related gastroenterology studies
- Medical Imaging Techniques and Applications
- Peptidase Inhibition and Analysis
- Pancreatitis Pathology and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Childhood Cancer Survivors' Quality of Life
- Neuropeptides and Animal Physiology
- Hormonal Regulation and Hypertension
- Medical Imaging and Pathology Studies
- Myasthenia Gravis and Thymoma
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
The Royal Free Hospital
2016-2025
University College London
2016-2025
Royal Free London NHS Foundation Trust
2015-2024
European Neuroendocrine Tumor Society
2012-2021
St. Vincent's University Hospital
2019
Trinity College Dublin
2019
Dana-Farber Cancer Institute
2017-2018
Moffitt Cancer Center
2018
County Hospital
2018
Ryhov Hospital Jönköping
2018
Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)–Dotatate in patients advanced, progressive, somatostatin-receptor–positive tumors.
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects limited.We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide patients advanced, well-differentiated or moderately differentiated, nonfunctioning, receptor-positive tumors grade 1 2 (a tumor proliferation index [on staining for Ki-67 antigen] <10%) and documented...
The need for standards in the management of patients with endocrine tumors digestive system prompted European Neuroendocrine Tumor Society (ENETS) to organize a first Consensus Conference, which was held Frascati (Rome) and based on recently published ENETS guidelines diagnosis treatment neuroendocrine (NET). Here, we report tumor–node–metastasis proposal foregut NETs stomach, duodenum, pancreas that designed, discussed, consensually approved at this conference. In addition, working...
be considered in three groups: the more frequent gastrinomas and insulinomas independently all rare F-P-NETs (RFTs) together as a separate category (Appendix 1 table ).Most P-NETs occur sporadic tumors (non-inherited), although variable proportion of different occurs part an inherited syndrome.MEN1 remains most important condition responsible for 20-30% <5% or RFTs [4][5][6][7] ; uncommon causes include von Hippel Lindau disease (VHL), Recklinghausen's syndrome (neurofibromatosis 1) tuberous...
These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from clinical committees British Gastroenterology, for Endocrinology, Association Surgeons Great Britain (and its Surgical Specialty Associations), Gastrointestinal Abdominal Radiology others. The authorship represents leaders various groups Society, but large amount work has carried out other specialists, many...
are not a homogenous entity and can be further subclassified into biologically relevant subgroups.A separation based on the proliferative index (Ki-67 >55%) was shown to have clinical implications regarding response chemotherapy prognosis: NEC with Ki-67 >55% responded better platinum-based and, nevertheless, had 4 months' shorter median survival than G3 NEN in lower range (20-55%) [1] .More recent publications show that morphological differentiation able separate prognostic groups among...
Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are also collectively known as midgut carcinoids. Similar to NETs in general, diagnosed incidence is on rise. Their presenting symptoms vary depending stage primary site. Local-regional often present with vague nonspecific symptoms. Classic carcinoid syndrome more likely appear patients advanced disease. small bowel should be resected whenever possible. With exception well-differentiated appendix, have...
Abstract BACKGROUND. The aim was to assess the relevant distribution of novel PET tracer 68 Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed (PET/CT) and compare its performance that 18 F‐FDG PET/CT. METHODS. imaging findings on 38 consecutive patients a diagnosis primary or recurrent NET were compared correlated tumor grade histology based ki67 mitotic index. RESULTS. sensitivity PET/CT 82% (31 38) 66% (25 38). 92% (35 There greater uptake...
Both the European Neuroendocrine Tumor Society (ENETS) and International Union for Cancer Control/American Joint Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems pancreatic neuroendocrine neoplasms. This study aims to identify most accurate useful system The included 1072 patients who had undergone previous surgery their cancer which at least 2 years of follow-up from 1990 2007 was available. Data on 28 variables were collected, performance two compared...
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact 177Lu-Dotatate treatment on time to health-related QoL. Methods The NETTER-1 trial an international phase III study patients midgut NETs. Patients were randomly assigned versus high-dose octreotide. European Organisation for Research and Treatment Cancer quality-of-life questionnaires QLQ C-30 G.I.NET-21 during determine completed at baseline every 12 weeks until...
<sup>111</sup>In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicine imaging modality of choice for identifying neuroendocrine tumors. However, there are cohorts patients in whom findings negative or equivocal. We evaluated role <sup>68</sup>Ga-DOTATATE PET a selected group with weakly positive on <sup>111</sup>In-DTPA-octreotide to determine whether able detect additional disease and, if so, patient management altered. <b>Methods:</b>...
Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated ethyl this setting. Patients and Methods (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, 250 mg, 500 mg three times orally during 12-week double-blind treatment period. The primary end point was...
Guidelines| December 29 2011 ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neoplasms Subject Area: Endocrinology , Neurology and Neuroscience Martyn Caplin; Caplin aDepartment Gastroenterology, Royal Free Hospital, London, UK; Search other works by this author on: This Site PubMed Google Scholar Anders Sundin; Sundin bDepartment Radiology, Marsden Sutton, Ola Nillson; Nillson cDepartment Pathology, Gothenburg University,...
Neuroendocrine tumors (NETs) are rare, slow-growing neoplasms characterized by their ability to store and secrete different peptides neuroamines.1 Some of these substances cause specific clinical syndromes,2 whereas other may have elevated plasma or urine levels that not associated with syndromes symptom complexes Unfortunately, there is no "ideal neuroendocrine tumor marker,"3 but according the presentation, sensitivity specificity each marker vary, it generally possible choose those...
We intended to identify the prognostic factors and results of interventions on patients with liver metastatic midgut carcinoids. Five institutions that are part United Kingdom Ireland neuroendocrine tumour (NET) group took in this study. Patients were included if they had histology proven NET origin metastases at time Clinical biochemical data collected retrospectively from hospital charts, pathology reports, radiology reports biochemistry records for each patient. Three hundred sixty The...
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from open-label extension (OLE). Patients grade 1/2 (Ki-67 ≤10%) non-functioning NET documented baseline tumour-progression status received 120 mg ( n =101) or placebo =103) for 96 weeks until death/progressive disease (PD) study. stable (SD) at...
This study aimed to assess the clinical impact of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG with respect management plan evaluate prognostic value both tracers. <b>Methods:</b> A total 104 patients (55 male 49 female; median age, 58 y; range, 20–90 y) histologically proven neuroendocrine tumors (NETs) underwent PET/CT. Twenty-eight (26.9%) had poorly differentiated tumors, 76 (73.1%) well-differentiated tumors. PET/CT results SUVs were compared factors such as histologic grade (G1, G2,...